Despite tangible progress in recent years, substantial therapeutic challenges remain in
multiple myeloma (MM), particularly for patients at high risk for early relapse or death and for …

Introduction: Survival in multiple myeloma (MM) has improved significantly in the past 10
years due to new treatments, such as thalidomide and lenalidomide (immunomodulatory …

Multiple myeloma (MM) is a hematological malignancy that remains incurable because most
patients will eventually relapse or become refractory to the treatments. Although the …

In vitro and in vivo models have been developed that have allowed for delineation of
mechanisms of multiple myeloma (MM) cell homing to bone marrow (BM); tumor cell …

Introduction: Multiple myeloma (MM) affected 14,400 new patients in the United States in
2002, and 50,000 total patients were affected. It remains incurable despite conventional and …

The past decade has witnessed a dramatic improvement in the therapeutic options in
multiple myeloma (MM). Several novel biologically targeted agents are in clinical use and …

Answer questions and earn CME/CNE Multiple myeloma (MM) is a cancer of antibody‐
producing plasma cells. The pathognomonic laboratory finding is a monoclonal …

In multiple myeloma, it is believed that multiple mutations in different pathways deregulate
the intrinsic biology of the plasma cell, resulting in a genetically complex heterogeneous …

The introduction of novel agents, such as bortezomib, thalidomide, and lenalidomide, into
daily practice has dramatically improved clinical outcomes and prolonged survival of …

Multiple myeloma (MM) is a genetically complex disease. Identification of mutations and
aberrant signaling pathways that contribute to the progression of MM and drug resistance …